Renal Denervation Catheters Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Renal Denervation Catheters Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Summary
GlobalData's Medical Devices sector report, “Renal Denervation Catheters Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update provides comprehensive information about the Renal Denervation Catheters pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Renal denervation, also known as renal sympathetic denervation (RSD), is a minimally invasive, catheter-based endovascular procedure that utilizes radiofrequency energy or ultrasound energy to ablate nerves in the walls of the renal artery, causing a reduction in the nerve activity which ultimately reduces the blood pressure in patients with resistant hypertension.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Extensive coverage of the Renal Denervation Catheters under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Renal Denervation Catheters and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Renal Denervation Catheters under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date
Introduction
Renal Denervation Catheters Overview
Products under Development
Renal Denervation Catheters - Pipeline Products by Stage of Development
Table Renal Denervation Catheters - Pipeline Products by Stage of Development
Table Renal Denervation Catheters - Pipeline Products by Stage of Development
Renal Denervation Catheters - Pipeline Products by Segment
Table Renal Denervation Catheters - Pipeline Products by Segment
Table Renal Denervation Catheters - Pipeline Products by Segment
Renal Denervation Catheters - Pipeline Products by Territory
Table Renal Denervation Catheters - Pipeline Products by Territory
Table Renal Denervation Catheters - Pipeline Products by Territory
Renal Denervation Catheters - Pipeline Products by Regulatory Path
Table Renal Denervation Catheters - Pipeline Products by Regulatory Path
Table Renal Denervation Catheters - Pipeline Products by Regulatory Path
Renal Denervation Catheters - Pipeline Products by Estimated Approval Date
Table Renal Denervation Catheters - Pipeline Products by Estimated Approval Date
Table Renal Denervation Catheters - Pipeline Products by Estimated Approval Date
Table Peregrine System Kit - Hypertension - A Pivotal, Multicenter, Blinded, Sham procedure-Controlled Trial of Renal Denervation by the Peregrine System Kit, in Subjects with Hypertension
Table Catheter Based Cryoablation System - Product Status
Table Catheter Based Cryoablation System - Product Description
Handok-Kalos Medical Company Overview
Handok-Kalos Medical Pipeline Products & Ongoing Clinical Trials Overview
Table Handok-Kalos Medical Pipeline Products & Ongoing Clinical Trials Overview
Table DENEX - Product Status
Table DENEX - Product Description
Table Handok-Kalos Medical - Ongoing Clinical Trials Overview
Table DENEX - A Prospective, Multicenter, No-treatment Controlled, Randomized, Open-label, Pivotal Study to Evaluate the Safety and Efficacy of DENEX, Renal Denervation Therapy, in Patients with Hypertension on no or 1-3 Antihypertensive Medications
Table DENEX - A Prospective, Multicenter, Sham-controlled, Single-blinded, Randomized, Pilot Study to Evaluate the Safety and Effectiveness of DENEX Renal Denervation System in Patients With Uncontrolled Hypertension Not Treated With Anti-HTN Medication
Johns Hopkins University Company Overview
Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview
Table Renal Denervation System - Product Description
Table Lepu Medical Technology (Beijing) Co Ltd - Ongoing Clinical Trials Overview
Table Disposable Intravascular Ultrasound Ablation Catheter - First in Man Study to Evaluate the Safety and Efficacy of Disposable Intravascular Ultrasound Ablation Catheters and Ultrasound Ablation Instrument in the Treatment of Essential Hypertension
Lifetech Scientific (Shenzhen) Co Ltd Company Overview
Table Symplicity Renal Denervation System - Global SYMPLICITY Registry (GSR) Denervation Findings in Real World (DEFINE)
Table Symplicity Renal Denervation System - Renal Denervation in Patients with Recurrent Atrial Fibrillation After Successful Pulmonary Vein Isolation (REDE-AF): A National, Multi-Centre, Prospective, Single-arm, Pre-to-post Treatment, Medical-Device Study
Table Symplicity Renal Denervation System - Study Evaluating the Clinical Evidence of Symplicity
Table Symplicity Spyral Renal Denervation System - Cardiac Sympathetic Neuromodulation by Renal Denervation in Hypertrophic Cardiomyopathy (SNYPER Pilot Study)
Table Symplicity Spyral Renal Denervation System - Global Clinical Study of Renal Denervation with the Symplicity Spyral Multielectrode Renal Denervation System in Patients with Uncontrolled Hypertension on Standard Medical Therapy (SPYRAL HTNON MED)
Table Symplicity Spyral Renal Denervation System - Prairie Renal Denervation Study: Renal Denervation (RDN) for Management of Patients with Loin Pain Hematuria Syndrome (LPHS)
Table Symplicity Spyral Renal Denervation System - Renal Nerve Simulation Guided Renal Sympathetic Denervation with Siymplicity Spyral Radiofrequency Catheter for Resistant Hypertension: a Feasibility Study
Table Symplicity Spyral Renal Denervation System - The SPYRAL AFFIRM Global Clinical Study of Renal Denervation with the Symplicity Spyral Renal Denervation System in Subjects with Uncontrolled Hypertension (SPYRAL AFFIRM)
Table Symplicity Spyral Renal Denervation System - The Systemic Effects of Transcatheter Renal Artery Sympathetic Denervation Using a Second- Generation Radiofrequency Ablation Catheter: A Multicenter Observational Study.
Table FlashPoint Renal Artery RF Ablation Catheter - 3D Cardiac Electrophysiological Mapping System on Renal Artery Radiofrequency Ablation System for Hypertension: a Prospective, Multicenter, Randomized Controlled Trial
Northwind Medical Inc Company Overview
Northwind Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table Paradise Ultrasound Renal Denervation System - Product Status
Table Paradise Ultrasound Renal Denervation System - Product Description
Table ReCor Medical Inc - Ongoing Clinical Trials Overview
Table Paradise Ultrasound Renal Denervation System - A Clinical Study of the Ultrasound Renal Denervation System (PRDS-001) in Patients With Hypertension
Table Paradise Ultrasound Renal Denervation System - Clinical Study of an Ultrasound Renal Denervation System in Patients with Heart Failure
Table Paradise Ultrasound Renal Denervation System - Effect of Renal Denervation in Hypertensive Patients With Autosomal Dominant Polycystic Kidney Disease
Table Paradise Ultrasound Renal Denervation System - Radiance Trio Continued Access Protocol (TRIO CAP): A Study of the ReCor Medical Paradise System in Clinical Hypertension
Table Paradise Ultrasound Renal Denervation System - Reducing Sympathetic Activity Through Ultrasound-based Renal Denervation in Excessive Cardiovascular Risk Populations - the RESURRECT Trial. A Pilot Proof-of-concept and Safety Study With the Paradise Denervation System
Table Paradise Ultrasound Renal Denervation System - Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients with Uncontrolled Hypertension: the RESTART Study
Table Paradise Ultrasound Renal Denervation System - The "Global Paradise System" Registry
Table Paradise Ultrasound Renal Denervation System - The Global Paradise(R) System US Post Approval Study (US GPS)
Table Paradise Ultrasound Renal Denervation System - Ultrasound-Based Renal Sympathetic Denervation as Adjunctive Upstream Therapy During Atrial Fibrillation - Redo Ablation Procedures: A Pilot Study
Table Therapeutic Intra-Vascular Ultrasound (TIVUS) System - Renal Artery Denervation - Clinical Evaluation of the Therapeutic Intra-Vascular Ultrasound (TIVUS) System for Renal Denervation in Patients with Uncontrolled Stage 2 Hypertension
Sound Interventions, Inc. Company Overview
Sound Interventions, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table Ultrasound Renal Denervation System - Product Status
Table Ultrasound Renal Denervation System - Product Description
St. Jude Medical LLC Company Overview
St. Jude Medical LLC Pipeline Products & Ongoing Clinical Trials Overview
Table St. Jude Medical LLC Pipeline Products & Ongoing Clinical Trials Overview
Table Third Generation EnligHTN Renal Denervation System - Product Status
Table Third Generation EnligHTN Renal Denervation System - Product Description
Suzhou Xinmai Medical Equipment Co Ltd Company Overview
Suzhou Xinmai Medical Equipment Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table Suzhou Xinmai Medical Equipment Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table SyMapCath I Catheter - Product Status
Table SyMapCath I Catheter - Product Description
Table Suzhou Xinmai Medical Equipment Co Ltd - Ongoing Clinical Trials Overview
Table SyMapCath I Catheter - A Prospective, Multicenter, Single Blind, Randomized and Controlled Trial of Renal Sympathetic Denervation Using SyMapCath I Catheter and SYMPIONEER S1 Stimulator/Generator for the Treatment of Hypertension (SMART Trial)
Table SyMapCath I Catheter - A Prospective, Single-center, Open-label, Self Controlled Case Series Trial of Renal Sympathetic Denervation Using SyMapCath I Catheter and SYMPIONEER S1 Stimulator/Generator for the Treatment of Hypertension in Patients on Hemodialysis: SMART-HD Trial
Table Verve Medical Phoenix System - Product Status
Table Verve Medical Phoenix System - Product Description
Table Verve Medical, Inc. - Ongoing Clinical Trials Overview
Table Verve Medical Phoenix System - Natural Orifice via Renal Pelvis Denervation (Novel- Denervation) Pivotal IDE Trial for the Treatment of Uncontrolled Hypertension to Lower Blood Pressure
Renal Denervation Catheters- Recent Developments
Jun 04, 2024: Medtronic Announces Dr. Goran Petrovski to Join Diabetes Medical Affairs Team
Jun 04, 2024: Medtronic Announces Retirement of Rob Ten Hoedt as Executive Vice President and President, Global Regions, Effective as of June 28, 2024
May 07, 2024: Medtronic's renal denervation system receives approval in China
Apr 18, 2024: Recor Medical Announces First Cases of Paradise Ultrasound Renal Denervation Therapy in the United Arab Emirates
Apr 11, 2024: Ablative Solutions' TARGET BP I Pivotal Trial Results Demonstrate Significant Reduction in 24-Hour Ambulatory Systolic Blood Pressure Compared to Sham, Using Alcohol-Mediated Renal Denervation
Mar 14, 2024: Tampa General Hospital Employs New Ultrasound Therapy Designed to Treat Life-Threatening Hypertension
Mar 12, 2024: Medtronic To Present At Barclays Global Healthcare Conference
Feb 28, 2024: Boston Scientific Raises $2.2B to Support Purchase of California Medical Device Company
Feb 23, 2024: Medical Tech Leader, Boston Scientific (BSX), Announces Notes Offering
Feb 19, 2024: Boston Scientific Appoints Madan Krishnan to Lead India Subcontinent
Feb 16, 2024: Jim Robo, Former Chairman and CEO of NextEra Energy, to Join Mayo Clinic Board of Trustees
Feb 07, 2024: Terumo Announces Change of Executive Officers (PDF 232.27 KB)
Feb 02, 2024: SoniVie completes enrolment in renal denervation study
Jan 31, 2024: Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
Jan 05, 2024: Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results
Dec 22, 2023: Medtronic Launches Symplicity Blood Pressure Procedure - A new Horizon in Managing Patients with Hypertension in India
Dec 19, 2023: Ablative Solutions Announces Primary Endpoint Met in the TARGET BP I Pivotal Trial of the Peregrine System Kit for Patients with Uncontrolled Hypertension
Dec 13, 2023: MarinHealth Interventional Cardiologists Are First on the West Coast to Perform Symplicity Renal Denervation Procedure Outside of a Clinical Trial
Dec 09, 2023: Baylor Scott & White Heart and Vascular Hospital - Dallas Deploys FDA-Approved Hypertension Treatment
Nov 28, 2023: Medtronic Obtains Pre-Market Approval (PMA) For Symplicity Spyral Renal Denervation System
Nov 28, 2023: First Patient Treated With Medtronic Symplicity Spyral Renal Denervation System at Piedmont
Nov 17, 2023: Medtronic Announces FDA Approval of Minimally Invasive Device to Treat Hypertension
Nov 16, 2023: ReCor Medical Obtains Pre-Market Approval (PMA) for Paradise Ultrasound Renal Denervation System
Nov 13, 2023: Recor Medical introduces Paradise uRDN system in US
Nov 08, 2023: Recor Medical receives FDA approval for hypertension treatment system
Oct 27, 2023: Positive six-month follow-up results for Recor's renal denervation system
Oct 26, 2023: Boston Scientific Announces Results for Third Quarter 2023
Oct 20, 2023: Recor Medical to Present Latest Clinical Data on Paradise Ultrasound Renal Denervation at TCT Annual Meeting
Oct 04, 2023: Medtronic Names Paolo Di Vincenzo President of the Neuromodulation Business
Aug 26, 2023: Medtronic Q2 2024 Earnings Estimates Increased by William Blair
Aug 23, 2023: Medtronic Issues Statement on the FDA Circulatory Systems Devices Advisory Panel Vote for the Symplicity Spyral Renal Denervation System
Aug 22, 2023: Otsuka Medical Devices and Recor Medical Announce Positive Vote from U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on the Paradise Ultrasound Renal Denervation System for the Treatment of Hypertension
Aug 17, 2023: Mayo Clinic Reports Strong Finances for 2023 So Far with Q2 Revenue of $4.47 billion
Aug 11, 2023: Kristin Peck, CEO of Zoetis, to join Mayo Clinic Board of Trustees
Aug 08, 2023: Medtronic to Announce Financial Results for its First Quarter of Fiscal Year 2024
Jul 19, 2023: Boston Scientific lays off 52 workers as it closes another Silicon Valley facility
Jul 14, 2023: ReCor Responds to European Society of Hypertension's (ESH) Updated Guidelines for Management of Arterial Hypertension
Jul 11, 2023: Verve Medical Announces FDA Approval of IDE for Pivotal Trial of RPD Renal Pelvic Denervation System for Treatment of Uncontrolled Hypertension
Jul 03, 2023: Medtronic Statement on ESH Guidelines for Hypertension and Renal Denervation
Jun 30, 2023: Bioheart Announces Clinical Result for Iberis-HTN at CIT 2023
Jun 27, 2023: Kalos Medical Receives Korean MFDS Innovative Medical Device Designation for DENEX Hypertension Treatment System